Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands

Albuminuria Clinical Trial

Official title:

Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04626271
• Other study ID #: ACR-US-MCU-01
• Status: Completed
• Phase: N/A
• Start date: August 31, 2020
• Est. completion date: October 25, 2020

Study information

• Verified date: April 2023
• Source: Healthy.io Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Eligible subjects meeting the pathological profile will be recruited at the designated site by the study personnel. Following subject consent, the subjects will be evaluated for eligibility based on their health condition and history.

The ACR | U.S. kit, in its original packaging, along with the ACR | U.S. smartphone application will be provided to the subject in a simulated home- use environment. All subjects will be provided with a list of tasks to complete, including providing a urine sample and operating the ACR | U.S. device on 2 mobile phones. After completing the test, the lay user will complete a post-test questionnaire. The study observer will also complete a questionnaire to collect information regarding the lay users' use of the ACR | U.S.

The device use will be compared with identified risks to determine if the percentage of failures is acceptable. Additionally, measurable usability criteria for specific, critical steps will be evaluated.

Following the usability test performed by the lay user, the subjects' urine samples will be tested by the study staff using the comparator device. These results will be considered as the "true value".

Recruitment information / eligibility

• Status: Completed
• Enrollment: 250
• Est. completion date: October 25, 2020
• Est. primary completion date: October 23, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Males and Females 18-80 years of age.

• Subjects diagnosed with a disease that normally represents itself with an abnormal concentration of albumin:

• Diabetes Type I/Type II,

• Hypertension,

• any kidney disease,

• other relevant conditions,

• or, subjects who are healthy or pregnant.

• Subject is familiar with the use of a smartphone.

• Subject is capable of comprehending and following instructions in English.

• Subject has facility with both hands.

• Subject is capable and willing to adhere to the study procedures.

• Subject is capable and willing to provide informed consent.

Exclusion Criteria:

• Subject has dementia.

• Subject has severe mental disorders.

• Subject cannot collect urine in a receptacle.

• Subject is visually impaired (cannot read the user manual).

• Any additional reason the study physician believes disqualifies the subject from participating in the study.

Related Conditions & MeSH terms

• Albuminuria

Intervention

Device:
• ACR | U.S. Urine Analysis Test System
Each study participant will test their urine sample using the ACR | U.S. test device - a home-use device intended for the semi-quantitative measurement of ACR in the urine (albumin and creatinine ratio) and used to aid in the management of kidney health.
• URiSCAN Optima Urine Analyzer
Upon completion of the test using the ACR | U.S. device, each urine sample will be provided to a professional user for further urine analysis test using the comparator device, the URiSCAN Optima Urine Analyzer.

Locations

Country	Name	City	State
United States	PMG Research of Charleston	Charleston	South Carolina
United States	AccuMed research associates	Garden City	New York

Sponsors (1)

Lead Sponsor	Collaborator
Healthy.io Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Accuracy Evaluation: The Degree of Agreement (%) of the ACR | U.S. Urine Analysis Test System as Compared to the Comparator Device	The primary objective of the study is to evaluate the % exact match (percent agreement) and the % ±1 block match (percent agreement) of ACR | U.S. Urine Analysis Test System (tested by the lay user) compared to the URiSCAN Optima Urine Analyzer (the comparator device, tested by a healthcare professional user), for all reported values (blocks). Different concentrations reported by the ACR | U.S. Urine Analysis Test System were compared with results from the comparator device.	2 months
Secondary	Usability Evaluation: User Performance Analysis	The usability of the ACR | U.S. Urine Analysis Test System was determined by evaluating the percentage of study subjects able to perform all required steps and successfully complete the test given only the instructions and training materials provided. In addition, each subject was asked to complete a post test questionnaire to assess the device ease of use by rating the various test steps on a scale of 1 to 5, with 5 being the easiest ("very easy") and 1 the hardest ("very hard"). This questionnaire also included understanding questions in a multiple-choice, quiz-like format, to assess the participants' understanding of essential information and key test procedures in the study.	2 months